

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Debosit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1615

THOMA ET AL.

Examiner: Yesbassa, Desta Letta

INTERNATIONAL APPLICATION NO: PCT/EP03/02446

FILED: 10 MARCH 2003

U.S. APPLICATION NO: 10/506,937

35 USC §371 DATE: 8 SEPTEMBER 2004

FOR: TASTED MASKED VETERINARY SOLID COMPOSITIONS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 8, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

A copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7922 Date: May 25, 2006

Novartis

David L. Marks
Attorney for Applicants

Reg. No. 37,881

05/30/2006 FFANAEIA 00000035 190134 10506937

01 FC:1806

180.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1615

THOMA ET AL.

Examiner: Yesbassa, Desta Letta

INTERNATIONAL APPLICATION NO: PCT/EP03/02446

FILED: 10 MARCH 2003

U.S. APPLICATION NO: 10/506,937

35 USC §371 DATE: 8 SEPTEMBER 2004

FOR: TASTED MASKED VETERINARY SOLID COMPOSITIONS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7922

Date: May 25, 2006

David L. Marks
Attorney for Applicants

Reg. No. 37,881

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AR

AS

ΑT

EXAMINER

ATTY. DOCKET NO. H-32407A APPLICATION NO. 10/506,937 APPLICANT THOMA ET AL. FILING DATE SEPTEMBER 8, 2004

Group 1615

MAY 2.5 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA							
	AB			-				
	AC							
	AD							
	AE			-				
, 1.00	AF							
	AG							
	АН							
	Al							
	AJ							
	AK					_		
	AL							
			FOREIG	ON PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATIO YES NO	
	AM	WO 96/01621	6/7/95	WIPO				
	AN							
	AO							
	AP							
	AQ		1		1		П	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED